The purpose of this research study is to learn more about the outcomes of total pancreatectomy with islet autotransplantation (TPIAT). Total pancreatectomy is the removal of the pancreas and islet autotransplantation is the placement of the insulin producing cells back into you to prevent diabetes. This study is looking to enroll patients who are scheduled to have a TPIAT surgery to treat pancreatitis (inflammation and scarring of the pancreas).
In addition to the routine care for pancreatitis and TPIAT surgery, participation in this study will involve completion of some brief surveys about the subject's health before TPIAT, at 6 months after TPIAT, and each year after the TPIAT surgery for 4 years, as well as a lab test conducted at each of the follow-up visits.
The purpose of this study is to test whether treatment with a drug called alpha 1 antitrypsin (AAT, Prolastin, Grilfols, Inc.) can reduce the chance of getting diabetes in a specific situation. Sometimes patients have their pancreas gland removed for pain. Since the pancreas makes insulin from cells called islet cells, these are removed from the pancreas and returned to the body to try decrease the chance of diabetes. The only participants invited to this study are those individuals getting ready to have the pancreas surgery.
This study is providing annual blood tests looking at diabetes autoantibodies for first degree relatives of patients diagnosed with type 1 diabetes who are between the ages of 1 and 45. It will also provide "diabetes screening" for second and third degree relatives age 1-20. Often parents and/or relatives wonder "if they will get diabetes" down the road or if additional offspring are "at risk" for type 1 diabetes. This study aims at assisting families with free blood testing. If positive, participants will be eligible for "prevention studies". MUSC is currently only participating in the "screening or Natural History" portion of TrialNet.